Treatment beyond progression with anti-PD-1/PD-L1 based regimens in advanced solid tumors: a systematic review.
Antineoplastic Combined Chemotherapy Protocols
/ adverse effects
B7-H1 Antigen
/ antagonists & inhibitors
Clinical Trials as Topic
Disease Progression
Humans
Immune Checkpoint Inhibitors
/ administration & dosage
Neoplasm Metastasis
Neoplasm Staging
Neoplasms
/ drug therapy
Programmed Cell Death 1 Receptor
/ antagonists & inhibitors
Treatment Outcome
Anti-PD-1
Immune-related response criteria
Immunotherapy
Melanoma
Treatment beyond progression
Journal
BMC cancer
ISSN: 1471-2407
Titre abrégé: BMC Cancer
Pays: England
ID NLM: 100967800
Informations de publication
Date de publication:
17 Apr 2021
17 Apr 2021
Historique:
received:
17
11
2020
accepted:
09
04
2021
entrez:
18
4
2021
pubmed:
19
4
2021
medline:
11
5
2021
Statut:
epublish
Résumé
Treatment beyond progression with immunotherapy may be appropriate in selected patients based on the potential for late responses. The aim of this systematic review was to explore the impact of treatment beyond progression in patients receiving an anti-PD-1/PD-L1 based regimen for an advanced solid tumor. A systematic literature search was performed to identify prospective clinical trials reporting data on overall response rate by immune-related criteria and/or the number of patients treated beyond conventional criteria-defined PD and/or the number of patients achieving a clinical benefit after an initial PD with regimens including an anti-PD-1/PD-L1 agent which received the FDA approval for the treatment of an advanced solid tumor. 254 (4.6%) responses after an initial RECIST-defined progressive disease were observed among 5588 patients, based on 35 trials included in our analysis reporting this information. The overall rate of patients receiving treatment beyond progressive disease was 30.2%, based on data on 5334 patients enrolled in 36 trials, and the rate of patients who achieved an unconventional response among those treated beyond progressive disease was 19.7% (based on 25 trials for a total of 853 patients). The results of our systematic review support the clinical relevance of unconventional responses to anti-PD-1/PD-L1-based regimens; however, most publications provided only partial information regarding immune-related clinical activity, or did not provide any information at all, highlighting the need of a more comprehensive report of such data in trials investigating immunotherapy for the treatment of patients with advanced tumors.
Sections du résumé
BACKGROUND
BACKGROUND
Treatment beyond progression with immunotherapy may be appropriate in selected patients based on the potential for late responses. The aim of this systematic review was to explore the impact of treatment beyond progression in patients receiving an anti-PD-1/PD-L1 based regimen for an advanced solid tumor.
METHODS
METHODS
A systematic literature search was performed to identify prospective clinical trials reporting data on overall response rate by immune-related criteria and/or the number of patients treated beyond conventional criteria-defined PD and/or the number of patients achieving a clinical benefit after an initial PD with regimens including an anti-PD-1/PD-L1 agent which received the FDA approval for the treatment of an advanced solid tumor.
RESULTS
RESULTS
254 (4.6%) responses after an initial RECIST-defined progressive disease were observed among 5588 patients, based on 35 trials included in our analysis reporting this information. The overall rate of patients receiving treatment beyond progressive disease was 30.2%, based on data on 5334 patients enrolled in 36 trials, and the rate of patients who achieved an unconventional response among those treated beyond progressive disease was 19.7% (based on 25 trials for a total of 853 patients).
CONCLUSION
CONCLUSIONS
The results of our systematic review support the clinical relevance of unconventional responses to anti-PD-1/PD-L1-based regimens; however, most publications provided only partial information regarding immune-related clinical activity, or did not provide any information at all, highlighting the need of a more comprehensive report of such data in trials investigating immunotherapy for the treatment of patients with advanced tumors.
Identifiants
pubmed: 33865350
doi: 10.1186/s12885-021-08165-0
pii: 10.1186/s12885-021-08165-0
pmc: PMC8052683
doi:
Substances chimiques
B7-H1 Antigen
0
CD274 protein, human
0
Immune Checkpoint Inhibitors
0
Programmed Cell Death 1 Receptor
0
Types de publication
Journal Article
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
425Références
Gastric Cancer. 2019 Jul;22(4):817-827
pubmed: 30515672
J Clin Oncol. 2015 May 1;33(13):1430-7
pubmed: 25452452
N Engl J Med. 2013 Jul 11;369(2):122-33
pubmed: 23724867
Lancet Oncol. 2019 Nov;20(11):1544-1555
pubmed: 31563517
Cancer. 2019 Oct 15;125(20):3603-3614
pubmed: 31251403
Lancet Oncol. 2016 Jul;17(7):883-895
pubmed: 27269741
Invest New Drugs. 2016 Jun;34(3):347-54
pubmed: 27000274
Lancet Oncol. 2018 May;19(5):694-704
pubmed: 29628312
Clin Cancer Res. 2020 Feb 15;26(4):837-845
pubmed: 31796519
Ann Oncol. 2018 Nov 1;29(11):2247-2253
pubmed: 30219915
N Engl J Med. 2012 Jun 28;366(26):2455-65
pubmed: 22658128
Clin Cancer Res. 2015 Nov 15;21(22):4989-91
pubmed: 26567357
PLoS Med. 2009 Jul 21;6(7):e1000097
pubmed: 19621072
Lancet Oncol. 2017 Nov;18(11):1493-1501
pubmed: 28988646
Lancet. 2016 May 7;387(10031):1909-20
pubmed: 26952546
Lancet Oncol. 2019 Jun;20(6):837-848
pubmed: 31078463
J Clin Oncol. 2016 Sep 10;34(26):3119-25
pubmed: 27269937
JAMA Oncol. 2018 Jan 1;4(1):93-97
pubmed: 28662235
J Clin Oncol. 2016 Sep 1;34(25):2980-7
pubmed: 27354485
Lancet Oncol. 2018 Jul;19(7):940-952
pubmed: 29875066
Lancet Oncol. 2018 Mar;19(3):416-426
pubmed: 29370992
Lancet Oncol. 2015 Apr;16(4):375-84
pubmed: 25795410
Lancet Oncol. 2017 Mar;18(3):312-322
pubmed: 28131785
Invest New Drugs. 2018 Feb;36(1):96-102
pubmed: 29119276
N Engl J Med. 2015 Jun 25;372(26):2509-20
pubmed: 26028255
Lancet Oncol. 2017 May;18(5):631-639
pubmed: 28314688
J Formos Med Assoc. 2020 Dec;119(12):1817-1826
pubmed: 32094063
Cancer. 2020 Feb 15;126(4):850-860
pubmed: 31747077
Lancet Oncol. 2018 Jan;19(1):51-64
pubmed: 29217288
J Immunother Cancer. 2018 Oct 22;6(1):111
pubmed: 30348224
N Engl J Med. 2015 Jan 22;372(4):320-30
pubmed: 25399552
JAMA Oncol. 2019 Mar 1;5(3):334-342
pubmed: 30347025
J Clin Oncol. 2014 Apr 1;32(10):1020-30
pubmed: 24590637
Clin Cancer Res. 2019 Apr 1;25(7):2174-2184
pubmed: 30670497
Lancet Oncol. 2018 Mar;19(3):347-355
pubmed: 29395863
J Thorac Oncol. 2018 Sep;13(9):1363-1372
pubmed: 29802888
J Clin Oncol. 2016 Sep 1;34(25):2969-79
pubmed: 27354481
Lancet Oncol. 2016 Nov;17(11):1590-1598
pubmed: 27733243
J Thorac Oncol. 2019 Oct;14(10):1794-1806
pubmed: 31228626
Lancet Oncol. 2016 Oct;17(10):1374-1385
pubmed: 27592805
Cancer Treat Rev. 2017 Sep;59:71-78
pubmed: 28756306
Cancer. 2019 Sep 15;125(18):3208-3218
pubmed: 31246283
J Clin Oncol. 2020 Sep 10;38(26):2981-2992
pubmed: 32167863
J Clin Oncol. 2015 Jun 20;33(18):2004-12
pubmed: 25897158
J Thorac Oncol. 2018 Nov;13(11):1733-1742
pubmed: 29775807
Breast Cancer Res Treat. 2018 Feb;167(3):671-686
pubmed: 29063313
J Thorac Oncol. 2018 Dec;13(12):1906-1918
pubmed: 30217492
N Engl J Med. 2015 May 21;372(21):2018-28
pubmed: 25891174
JAMA Oncol. 2016 Sep 1;2(9):1179-86
pubmed: 27243803
Lancet Oncol. 2015 Aug;16(8):908-18
pubmed: 26115796
N Engl J Med. 2015 Oct 22;373(17):1627-39
pubmed: 26412456
J Clin Oncol. 2015 Jun 20;33(18):2013-20
pubmed: 25800770
Lancet Oncol. 2017 Feb;18(2):212-220
pubmed: 28081914
JAMA Oncol. 2019 Mar 1;5(3):393-401
pubmed: 30676622
J Clin Oncol. 2016 May 1;34(13):1510-7
pubmed: 26951310
Eur Urol. 2017 Sep;72(3):368-376
pubmed: 28410865
Lancet Oncol. 2016 Mar;17(3):299-308
pubmed: 26858122
J Clin Oncol. 2020 Jan 1;38(1):71-80
pubmed: 31644329
J Immunother Cancer. 2020 Mar;8(1):
pubmed: 32188704
Clin Cancer Res. 2009 Dec 1;15(23):7412-20
pubmed: 19934295
J Clin Oncol. 2020 Apr 10;38(11):1138-1145
pubmed: 32097091
JAMA. 2016 Apr 19;315(15):1600-9
pubmed: 27092830
JAMA Oncol. 2018 May 1;4(5):717-721
pubmed: 29423503
Lancet Oncol. 2016 Jul;17(7):956-965
pubmed: 27247226
Lancet Oncol. 2017 Mar;18(3):e143-e152
pubmed: 28271869
N Engl J Med. 2017 Oct 5;377(14):1345-1356
pubmed: 28889792
J Thorac Oncol. 2018 Oct;13(10):1569-1576
pubmed: 29908324
Lancet Oncol. 2020 Feb;21(2):294-305
pubmed: 31952975
Nature. 2014 Nov 27;515(7528):558-62
pubmed: 25428503
N Engl J Med. 2015 Jul 9;373(2):123-35
pubmed: 26028407
Lancet Oncol. 2017 May;18(5):599-610
pubmed: 28373005
J Clin Oncol. 2019 Oct 1;37(28):2518-2527
pubmed: 31154919
Eur J Cancer. 2019 Jan;107:124-132
pubmed: 30562710
Lancet Oncol. 2018 May;19(5):672-681
pubmed: 29602646
N Engl J Med. 2017 Jun 22;376(25):2415-2426
pubmed: 28636851
JAMA Oncol. 2019 Jan 1;5(1):74-82
pubmed: 30242306
Lancet Oncol. 2018 Feb;19(2):229-239
pubmed: 29361469
J Clin Oncol. 2015 Dec 1;33(34):4015-22
pubmed: 26351349
J Clin Oncol. 2016 Mar 10;34(8):833-42
pubmed: 26755520
Lancet Respir Med. 2018 Jun;6(6):451-460
pubmed: 29773326
Lancet Oncol. 2018 Mar;19(3):405-415
pubmed: 29439857
Lancet Oncol. 2016 Jul;17(7):976-983
pubmed: 27267608
Lancet Oncol. 2015 Mar;16(3):257-65
pubmed: 25704439
Nat Commun. 2016 Aug 30;7:12624
pubmed: 27571927
Lancet. 2017 Dec 2;390(10111):2461-2471
pubmed: 28993052